ID: ALA3763214

Max Phase: Preclinical

Molecular Formula: C22H17Cl2N3O5

Molecular Weight: 474.30

Molecule Type: Small molecule

Representations

Canonical SMILES:  COC(=O)c1c2nc3ccc(N(C)C)cc3oc-2c(O)c(=O)c1Nc1ccc(Cl)c(Cl)c1

Standard InChI:  InChI=1S/C22H17Cl2N3O5/c1-27(2)11-5-7-14-15(9-11)32-21-18(26-14)16(22(30)31-3)17(19(28)20(21)29)25-10-4-6-12(23)13(24)8-10/h4-9,25,29H,1-3H3

Standard InChI Key:  QEAMPRBYGQHTAE-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 474.30

Molecular Weight (Monoisotopic): 473.0545

AlogP: 4.90

#Rotatable Bonds: 4

Polar Surface Area: 104.90

Molecular Species: NEUTRAL

HBA: 8

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 7.81

CX Basic pKa: 3.01

CX LogP: 4.30

CX LogD: 4.16

Aromatic Rings: 2

Heavy Atoms: 32

QED Weighted: 0.32

Np Likeness Score: -0.79

References

1. Thysiadis S, Mpousis S, Avramidis N, Katsamakas S, Balomenos A, Remelli R, Efthimiopoulos S, Sarli V..  (2016)  Discovery of novel phenoxazinone derivatives as DKK1/LRP6 interaction inhibitors: Synthesis, biological evaluation and structure-activity relationships.,  24  (5): [PMID:26819000] [10.1016/j.bmc.2016.01.025]

Source

Source(1):

• Scientific Literature